Aquestive Therapeutics Stock Alpha and Beta Analysis
| AQST Stock | USD 3.08 0.02 0.65% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Aquestive Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Aquestive Therapeutics over a specified time horizon. Remember, high Aquestive Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Aquestive Therapeutics' market risk premium analysis include:
Beta (0.21) | Alpha (0.78) | Risk 4.08 | Sharpe Ratio (0.19) | Expected Return (0.78) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Aquestive |
Aquestive Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Aquestive Therapeutics market risk premium is the additional return an investor will receive from holding Aquestive Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Aquestive Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Aquestive Therapeutics' performance over market.| α | -0.78 | β | -0.21 |
Aquestive Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Aquestive Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Aquestive Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Aquestive Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Aquestive Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Aquestive Therapeutics shares will generate the highest return on investment. By understating and applying Aquestive Therapeutics stock market price indicators, traders can identify Aquestive Therapeutics position entry and exit signals to maximize returns.
Aquestive Therapeutics Return and Market Media
The median price of Aquestive Therapeutics for the period between Sat, Nov 2, 2024 and Fri, Jan 31, 2025 is 3.85 with a coefficient of variation of 20.82. The daily time series for the period is distributed with a sample standard deviation of 0.86, arithmetic mean of 4.13, and mean deviation of 0.77. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Krop Julie of 38000 shares of Aquestive Therapeutics at 2.5 subject to Rule 16b-3 | 11/01/2024 |
2 | Leerink Partnrs Has Strong Estimate for AQST FY2024 Earnings | 11/08/2024 |
3 | ARMISTICE CAPITAL, LLC Acquires New Stake in Aquestive Therapeutics Inc | 11/15/2024 |
4 | Short Interest in Aquestive Therapeutics, Inc. Declines By 6.0 | 11/19/2024 |
5 | Disposition of tradable shares by Cassie Jung of Aquestive Therapeutics at 4.865 subject to Rule 16b-3 | 11/26/2024 |
6 | Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm Sublingual Film | 12/02/2024 |
7 | Aquestive Therapeutics shareholders have earned a 88 percent return over the last year | 12/16/2024 |
8 | Aquestive Therapeutics investors will be pleased with their favorable 88 percent return over the last year | 12/17/2024 |
9 | Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five | 12/19/2024 |
10 | Aquestive Therapeutics, Inc. Given Consensus Rating of Buy by Analysts - MarketBeat | 01/15/2025 |
11 | Disposition of 56824 shares by Daniel Barber of Aquestive Therapeutics at 4.88 subject to Rule 16b-3 | 01/24/2025 |
About Aquestive Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Aquestive or other stocks. Alpha measures the amount that position in Aquestive Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 1.95 | 2.33 | 2.1 | 1.51 | Days Of Inventory On Hand | 108.83 | 118.61 | 106.75 | 67.92 |
Aquestive Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Aquestive Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aquestive Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Aquestive Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Aquestive Therapeutics. Please utilize our Beneish M Score to check the likelihood of Aquestive Therapeutics' management manipulating its earnings.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Aquestive Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.